[HTML][HTML] Cyclophosphamide, thalidomide, and dexamethasone as induction therapy for newly diagnosed multiple myeloma patients destined for autologous stem-cell …
GJ Morgan, FE Davies, WM Gregory, SE Bell… - …, 2012 - ncbi.nlm.nih.gov
Haematologica, 2012•ncbi.nlm.nih.gov
Cyclophosphamide, thalidomide, and dexamethasone as induction therapy for newly diagnosed
multiple myeloma patients destined for autologous stem-cell transplantation: MRC Myeloma IX
randomized trial results - PMC Back to Top Skip to main content NIH NLM Logo Access keys
NCBI Homepage MyNCBI Homepage Main Content Main Navigation Search PMC Full-Text
Archive Search in PMC Advanced Search User Guide Journal List Haematologica v.97(3); 2012
Mar PMC3291601 Other Formats PubReader PDF (1022K) Actions Cite Collections Share …
multiple myeloma patients destined for autologous stem-cell transplantation: MRC Myeloma IX
randomized trial results - PMC Back to Top Skip to main content NIH NLM Logo Access keys
NCBI Homepage MyNCBI Homepage Main Content Main Navigation Search PMC Full-Text
Archive Search in PMC Advanced Search User Guide Journal List Haematologica v.97(3); 2012
Mar PMC3291601 Other Formats PubReader PDF (1022K) Actions Cite Collections Share …
Abstract
Background
Thalidomide is active in multiple myeloma and is associated with minimal myelosuppression, making it a good candidate for induction therapy prior to high-dose therapy with autologous stem-cell transplantation.
ncbi.nlm.nih.gov
